Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
7.45
-0.05 (-0.67%)
At close: Apr 28, 2026, 4:00 PM EDT
7.60
+0.15 (2.01%)
After-hours: Apr 28, 2026, 6:59 PM EDT
Solid Biosciences Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Solid Biosciences stock have an average target of 16.36, with a low estimate of 9.00 and a high estimate of 26. The average target predicts an increase of 119.60% from the current stock price of 7.45.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 25, 2026.
Analyst Ratings
The average analyst rating for Solid Biosciences stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 4 | 4 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +61.07% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +168.46% | Mar 23, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +248.99% | Mar 20, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +101.34% | Mar 20, 2026 |
| Needham | Needham | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +155.03% | Mar 20, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
13.57M
EPS This Year
-1.69
from -1.99
EPS Next Year
-1.72
from -1.69
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 86.3M | ||||||
| Avg | n/a | 13.6M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.45 | -1.19 | ||||||
| Avg | -1.69 | -1.72 | ||||||
| Low | -2.12 | -2.05 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.